S&P Global Ratings projects Glenmark Pharmaceuticals will achieve a net cash positive position following its licensing agreement with AbbVie Inc. This deal, concerning ISB 2001, is expected to significantly strengthen Glenmark's financial standing and liquidity, reversing a previous net debt.